The demand for human immunoglobulin is invariably increasing on an annual basis. To satisfy demands, different manufacturing processes are used to isolate immunoglobulins from human plasma. A quest for alternative paths in manufacturing not only requires development of the most economical manufacturing process, but also a rapid method development and development of reliable analytics for manufacturing monitoring. For an efficient improvement of the purification methods as well as for in-process control during manufacturing stage, the usage of reliable and fast analytical techniques are of crucial importance.
Fast and reliable fingerprint-based method for characterization of immunoglobulin G (IgG) prepared from Cohn I+II+III paste in two chromatographic steps is presented. The fingerprint method bases on partial separation of proteins in linear gradient on CIMac QA 0.1 mL column. Partial separation of proteins does not allow simple quantitative analysis of the samples during the IgG production from Cohn I + II + III paste, however, a very accurate qualitative information about the composition of the sample can be obtained in less than 5 minutes.
The challenge of efficient purification of gene therapy vectors
• The most commonly used gene transfer vectors are adenoviruses, lentiviruses, adeno-associated viruses, retroviruses, vaccinia viruses, and pDNA
• Due to their large size and sensitivity to pH, temperature and shear stress, purification is challenging and time-consuming
• A fast and efficient downstream processing purification method is required to isolate sufficient amounts of vectors with the final purity and state that conforms to stringent regulatory demands.
Solution: Convective Interaction Media Monoliths
• Convective interaction media (CIM) monolith chromatography
• Functionalised polydimethacrylate (QA, DEAE, OH, SO3)
• Precisely defined pore sizes
• Radial flow of solute
• Convective mass transfer
The development of safe, effective, and affordable vaccines has become a global effort due to its vast impact on overall world health conditions. A brief overview of cancer vaccine characterization techniques, especially in the area of high-resolution mass spectrometry, is presented. It is highly conceivable that the proper use of advanced technologies such mass spectrometry, along with the appropriate chemical and physical property evaluations, will yield tremendous in-depth scientific understanding for the characterization of vaccines in various stages of the development. This work presents the physiochemical and biological characterization of two cancer vaccines: Racotumomab and Her1-ECD. Racotumomab monoclonal antibody is a murine anti-idiotypic antibody that mimics N-glycolyl-GM3 gangliosides. This antibody has been tested as an anti-idiotypic cancer vaccine, adjuvated in Al(OH)3, in several clinical trials for melanoma, breast, and lung cancer. The Her1-ECD is a vaccine preparation based on the extracellular domain of HER1 and it is being evaluated in Phase I clinical study in patients with refractory prostate cancer.
A monolith is a stationary phase made of single piece of porous material. Unlike conventional particle-shaped chromatographic supports, the pores of the monolith are interconnected and form a network of channels with diameters ranging around 1500 nm. The binding sites in these channels are highly accessible for target molecules and since the predominant mass transfer depends on convection rather than diffusion, the dynamic binding capacity is flow independent. These characteristics make the monolithic supports suitable for fast separation and purification of large biomolecules such as proteins, DNA and viruses, which sometimes exceed 200 nm in size and thus have low diffusion constants.
In this work we tried to quantify influenza A virus using an analytical CIM monolith column. First a screening of available CIM stationary phases was performed in order to establish the optimal stationary phase for the binding of the virus. The effect of the mobile phase composition and pH on the recovery and peak shape of the virus was investigated. Linearity was examined. The amount of virus in the flow-through and elution fractions was determined with the haemagglutination assay and the purity of the fractions with SDS PAGE. All experiments were performed with an inactivated Influenza A/Wisconsin PZC whole virus sample that was produced in eggs.
Monolith chromatography media coupled with metal affinity ligands proved superior to the conventional particle-based matrix as a plasmid DNA (pDNA) purification platform. By harnessing the differential affinity of pDNA, RNA. Host cell proteins and endotoxin to copper ions in the solution a majority of endotoxin (90%) was removed from the alkaline cell lysate using CuCl2-induced precipitation. RNA and remaining endotoxin were subsequently processed by copper immobilized metal affinity column employing either monolith or particle-based matrix where both RNA and endotoxin were removed below detection limit with almost complete recovery of pDNA in the monolith was found to have several advantages in terms of handling feedstocks crowded with RNA in a concentration-independent manner and exhibiting flowrate-independent dynamic binding capacity for RNA. This enabled monolith-based process to be conducted at high feed concentration and flow rate. Resulting in pDNA vaccine purification at a high yield and purity and the process conditions investigated, the use of monolith column gave at least three fold higher productivity for recovery of purified pDNA as compared to the particle- based column, demonstrating its potential as a more rapid and economical platform for pDNA vaccine purification.
The present study describes a new methodology to quantify and monitor the quality of supercoiled (sc) plasmid DHA (pDLIA), using a monolithic column based on anion-exchange chromatography. This analytical method with UV detection allows distinguishing the plasmid isoforms by a NaCl stepwise gradient. The selectivity, Linearity, accuracy, reproducibility and repeatability of the method have been evaluated, and the lower quantification and detection limits were also established. The validation was performed according to the guidelines, being demonstrated that the method is precise and accurate for a sc plasmid concentration up to 200 µg/mL. The main advance achieved by using this monolithic method is the possibility to quantify the sc plasmid in a sample containing other plasmid topologies, in a 4 minutes experiment. This work also intends to evaluate the possibility to assess the sc pDNA present in more complex samples, allowing the control of the samples recovered from different bioprocess steps.
Glycosylation is one of nature mechanism for invreasing the diversity of protein structures affecting biophysical vjaracterostocs and bioactivity. Glycoproteins exist as mixture of different isoforms ("glycoforms"). In this mixture a group od different glyco components is attached to individual glycosylation site. Different glyco componets attached to the same site may have diggerent effect on biophysical charachteristics of glycoproteins. The type of glycosylation and the degree of heterogenity are important for many reasons starting from stability, activity, clinical efficency (toxicity, pharmacokinetics, immunogenicity), to standardization and patentability.
Thus, it is necessary to separate glycoforms and as much as possible to difine the heterogenity i.e. population of of glyco components attached to the singele glycosysilation site.
External invertase is a widely usef model for studying the influance of the glyco-component on protein stability. External invertase from yeast Sccharomyces cerevisiae has 14 potential N-glycosylation sites in the sequence, 13 of which are fully or partially glycosylated with olygomannans of varying sizes.
Extensive research in the last two decades has led to the realization of Immunoglobulin M (IgM) as a potential therapeutic and diagnostic agent for autoimmune diseases, infectious diseases and as an AIDS and cancer vaccine. Growing interest in these molecules has created a need for an accurate, rapid and simple analytical method to measure IgM concentrations during the production (in-process control) in cell culture supernatants as well as in all purification steps in the downstream processing.
Convective interaction media (CIM) monolithic columns has been increasingly recognized as a quantification tool for large molecules. Affinity ligands like protein A and protein G are the most common ligands used for antibody capture and analysis.
Recombinant Adenovirus (rAd) is commonly used for vaccination and gene transfer for cancer applications. This vector is widely used in phase I/II clinical trials. Therefore we believe that upstream and downstream processes should be improved.
We developed a production manufacturing process for rAd serotype 5 n HEK293 grown into disposable fixed-bed iCELLis™ bioreactors (ATMI LifeSciences). The purification process was reduced to one single chromatography step using the Convective Interaction Media, anion exchanger (CIM ® QA monolithic column, Bia Separations).
Briefly, rAd particles were extracted from cells using Triton X-100, depth filtered to discard cell debris, captured and purified out on CIM ® QA. The shallow gradient used for the elution of the vector allowed the separation of different rAd particles populations more or less enriched in full particles. A final step based on Tangential Flow Filtration (TFF) in hollow fibers allowed the removal of remaining impurities and the formulation of the vector batch.
In addition, we developed an analytical method on CIMac™ QA analytical column (Bia Separations) to characterize the different steps of the process, and to track the differences linked to the production runs to increase the robustness of the process. This method provided elution profiles for each step as well as titer of the purified rAd in the final step.
The rAd was produced in an iCELLis™ nano fixed-bed bioreactor (0.5-5.3 m2), purified in a 8mL CIM ® QA monolithic column, scaled up in a medium-scale size 80mL column. We are currently extending the rAd production in a 133m2 iCELLis I000™ bioreactor with a purification step using a 8L CIM® QA monolithic column to purify out up to 1x1015 vector particles.
Monolithic supports represent a new generation of chromatographic media. Due to their large inner channel diameters and enhanced mass transfer characteristics, methacrylate monoliths (CIM® monolithic columns) offer efficient and fast separation of large biomolecules like pDNA, viruses and monoclonal antibodies. High binding capacity for viral particles, good product recovery and resolution are also benefits of monoliths. During loading of MDCK cell-derived H1N1 inactivated influenza virus particles onto monolithic columns, increased back pressure is sometimes observed. This is especially an issue if a large amount of virus needs to be purified since the back pressure depends on the loading volume. The goal of this work was to determine the factors contributing to this effect. We tried to prevent the increased back pressure by treating virus harvests with different precolumn phases (LRATM - Lipid removal agent, Amberlite® XAD 7HP, epoxy monolithic column) and by filtering the virus material before loading it onto the column. To compare different pre-treatment strategies of the virus material the dynamic binding capacity of CIMac QA for virus was first determined, resulting in approximately 1x1013 virus particles per ml. Than loadings of the pre-treated virus material at 75% of the column capacity were performed and mass balances for the virus, DNA and proteins were investigated. Another goal of this work was to find a good regeneration strategy for the columns where increased back pressure occurred. For this reason different regeneration procedures using lipase, benzonase, 2-propanol and NaOH treatment were tested on the columns with increased back pressure.
Traditional waste water treatment usually does not remove or inactivate all of the potentially pathogen microorganisms present in the waste water. This is especially true for enteric viruses that are introduced into the environment through the discharge of effluent from waste water treatment plants - WWTP (Simmons et al, 2011). Although discharged concentrations of viruses are low they can still lead to infection. For some enteric viruses ingestion of only 10 - 100 virus particles is enough to initiate the disease, what calls for very sensitive detection methods. It has been previously shown that CIM-quaternary amine (QA) monolithic supports are a good tool for concentration of viruses in water (Gutierrez-Aguirre et al, 2011). Here we go one step further and evaluate CIM monoliths not just for concentration of enteric viruses but also for their removal from effluent waters.
Potato spindle tuber viroid (PSTVd) is the causal agent of a number of agriculturally important diseases. It is a single-stranded, circular and uncapsidated RNA molecule with 359 nucleotides and no coding capacity. Because of its complex secondary/tertiary structure it is very stable ex vivo and it is easily transmitted mechanically by contaminated hands, tools, machinery, etc. In this work, we describe the development and optimization of a method for concentrating PSTVd using CIM monolithic supports.
Objective – Influenza VLP
• Complex structure
• Different protein components
• Host cell derived lipid membrane
• ESAT6 epitope of M. tuberculosis engineered into influenza hemagglutinin [1,2]
• Optimal vaccine candidates
• Induce strong immune response 
• Contain no genetic information
There is an increasing demand for highly purified immunoglobulin G since they have found wide range of potential application in immunodiagnostics and immunotherapy.
Human IgG (hIgG) consists of four subclasses (IgG1, IgG2, IgG3 and IgG4) that show differences in some of their physicochemical characterictics and biological properties.
The present research project aims to separate subclasses of hIgG using monolithic stationary phase by SMB technology.
Over the last two decades,the potential of virus-based biopharmaceuticals for application in gene therapy and vaccination brought new challenges in bioprocess development. Particularly, the downstream processing (DSP) of enveloped viruses shifted from bench-scale towards robust, scalable and cost-effective strategies to produce clinical grade viralvectors. Lenti viralvectors(LVs) hold great potential in gene therapy due to their ability to transduce non dividing cells and their capacity to sustain long-term transgene expression in several target cells, invitro and invivo1. However, despite significant progress, the quality of LV preparations, the purification and the concentration of high titers of these vectors is still cumbersome and costly. In this work, disposable membrane technologies, involving microfiltration, anion-exchange chromatography (AEXc) and a final ultrafiltration step, were the basis for the development of an optimized purification process for LV.
Application of plasmid DNA for gene therapy and vaccination has gained huge interest in last two decades. Topological homogeneity and impurity content are crucial for therapeutic usage of pDNA. Major influence on achieving regulatory demands in pDNA production has downstream processing and in order to get optimal purity different purification techniques have to be included. It was demonstrated that methacrylate monoliths can be used for efficient purification process of plasmid DNA. High dynamic binding capacities and high flow rates of methacrylate monolith enabled excelent purity and productivity.
Over the last years, lentiviral vectors have emerged as valuable tools for transgene delivery because of their ability to transduce non-dividing cells and their capacity to sustain long-term transgene expression in target cells in vitro and in vivo. However, despite significant progress, the purification and concentration of high titer and high quality vector stocks is still time-consuming and scale-limited. We aimed to develop a simple and cost-effective capture purification step capable of separating the produced lentiviral vectors from the preparation originally containing a load of recombinant baculoviruses used to transiently transfect 293T producer cells. Even though recombinant baculoviruses do not present major safety concerns1, the final product (purified lentiviral vectors) should be pure enough to be tested in (pre-)clinical studies2. A capture step has been preliminarily evaluated. Both lentiviruses and baculoviruses are enveloped, thus per se prone to degradation through processing. Furthermore, both show overall surface negative charges at physiological pH3,4. As such, our rationale was to use an anion-exchange bind-elute step with enough resolution to separate the two viruses upon elution. It was likely that the difference in the overall electrostatic charges of the two viruses can be used to our advantage if a sufficiently extended salt elution gradient is used.
Biomanufacturing of antibodies, therapeutic proteins and vaccines or gene delivery vectors (either DNA or virus based) is a very complicated process where many things can go wrong. This is even more pronounced as the target biomolecules are extremely susceptible to the environmental conditions both during cultivation (upstream processing) as well as during isolation and purification (downstream processing). One can always doubt whether we have enough information about our complex biomolecule samples to consistently develop a safe product by running a robust and efficient purification bioprocess.
By using and understanding novel technologies one can design new process analytic technology (PAT) initiatives to overcome some of these problems. Here, we present novel monolithic analytical columns — CIMac columns — that can bridge this gap. In the first example, CIMac columns were applied for monitoring the purification process of virus like particles (VLP) which are used for production of vaccines and as delivery systems in gene therapy. In the second example, the monolithic analytical columns were also applied for monitoring the fermentation process of bacteriophages.
Avir Green Hills Biotechnology is developing innovative seasonal and pandemic influenza vaccines based on the deletion of the NS1 gene (del NS1 vaccine).The vaccine is replication-defective and applied intranasally. Recently,clinical phase I studies for H1N1 monovalent vaccine and H5N1 avian influenza vaccine were completed. Both were confirmed to be safe and immunogenic for humans. A production and purification process, which was successfully employed for the pilot-scale production of H1N1 and H5N1 influenza A vaccine virus, will be presented and compared to standard ultracentrifugation method. Details on obtained life virus yields as well as impurity removal will be given. The vaccine virus is produced in static cell culture using Vero (African Green monkey kidney) cells. After clarification the vaccine virus bulk is purified using the same(chromatography-based) scheme for all different subtypes: Concentration by tangential ultrafiltration, AEX chromatography using a CIM QA monolith, and an SEC polishing step allowing for buffer exchange. This purification scheme guarantees the thorough depletion of host cell DNA and total protein. For the ultracentrifugation approach chromatographic steps were replaced by a gradient ultracentrifugation step, comparison data are shown. In addition, an HPLC method for quantifying influenza virus in the vaccine with the use of CIM monolithic columns will be presented and the results will be compared with haemagglutination method.
Rabies virus cause acute encephalitis. It is widely distributed around the globe and more than 55,000 people perish yearly and an additional 10 million post-exposure treatment are reported. About 95% of human deaths occur in Asia and Africa. In countries that are endemic to rabies an immense need for cost-effective large-scale production of the Rabies vaccine occurs. Achieving required quality is challenging because majority of rabies vaccines are produced in Vero cells. This makes Rabies vaccine difficult to manufacture due to low titre of vaccine with lots of residual cellular DNA and serum proteins.
The objective of this work was to improve purity of rabies vaccine regarding residual DNA presence. Different mobile phases with different pH values were explored. Moreover, to develop cost-efficient downstream process for Rabies vaccine, monolith-based purification step was performed in different stages of downstream processing. Chromatographical fractions were analyzed for efficiency of DNA removal. In addition, recovery of Rabies vaccine was monitored. Finally, knowing the optimal conditions, a step-wise gradient was used for purification of larger amount of Rabies vaccine.